Broad applications in cell based assays, ranging from cell therapy and regenerative medicine to drug discovery and diagnostics.
Drug Discovery /
Pooled high content phenotypic screens of genes and drugs compatible with multiple libraries including CRISPR gRNAs, shRNAs, antibodies, and even small compounds.
Pooled High-Content Screening of
Genes and Drugs
Our Solution for Cell Therapy
Image-based high-content screening (HCS) is a powerful method for identifying genes and compounds that induce physiologically relevant disease-linked cellular phenotypes. However, it is time-consuming and expensive owing to its reliance on well-to-well imaging of microplates. In contrast, a pooled screen offers a high throughput and cost effective method involving conventional flow cytometry. However, the readouts are limited to fluorescence and light scattering from known biomarkers.
Using ThinkCyte’s proprietary machine Vision-based Cell Sorting (ViCS) technology, we have developed a new method that enables high-throughput image-based HCS in a pooled format. This novel method is compatible with various types of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small compounds.
Key Advantages of Our Technology
- Applicable to
a variety of libraries
- Usable to your own compound, CRISPR, shRNA, peptide, phage libraries, etc.
- Applicable to
- High speed sorting
- Pathway-specific libraries: 1–3 h
- Whole-genome libraries: 8–12 h
- Compound libraries (~100,000 compounds): 1–3 d
- For precious cells
- Only a few hundred cells per gene/compound are required for screening
- Link genotypes to phenotypes
- Image data is linked to the NGS data
- Reduce reagents, labor, and analysis time
Phenotype-driven Target Validation in Drug Discovery
In the phenotypic screening process, identification of disease relevant phenotypes is crucial. Our screening platform is able to detect various types of phenotypes, such as changes in protein localization, aggregation, and cell and organelle morphology, using fluorescence reporters. Furthermore, our proprietary machine vision-based classification technique can discriminate morphological differences of cells including live and apoptotic cells, differentiated and undifferentiated cells, and healthy and disease relevant cells, without the use of molecular labels. These label-free phenotypes can be also used in our screening system.
Disease-relevant phenotypes of cells
- Apoptotic Status
- Disease vs Healthy
Our screening platform enables image-based high-content screens in a pooled format that can dramatically accelerate the screening process while reducing costs. It is compatible with a wide range of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small compounds.
Pooled screening of genes
Our technology is applicable for screening of genes using lentivirus libraries including CRISPR library.
Pooled screening of drugs
Combining our proprietary ViCS technology with DNA barcoding and droplet techniques, image-based high-content screens can be performed for small molecule libraries in a pooled format as well.
GET IN TOUCH
Interested in our technology?
Contact us to be part of our early access program.